Price
CHART BY
Frequently asked questions
What is Rocket's market capitalization?
The market capitalization of Rocket is $1.23B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Rocket?
Rocket's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.754. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Rocket's stock?
Currently, 16 analysts cover Rocket's stock, with a consensus target price of $45.21. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Rocket?
Rocket's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$264.44M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Rocket?
Rocket has a free cash flow of -$202.43M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Rocket have, and what sector and industry does it belong to?
Rocket employs approximately 268 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Rocket's shares?
The free float of Rocket is 96.86M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.23B
- EPS (TTM)
- -$2.754
- Free Float
- 96.86M
- EBITDA (TTM)
- -$264.44M
- Free Cashflow (TTM)
- -$202.43M
Pricing
- 1D span
- $11.58$11.62
- 52W span
- $11.15$32.45
Analyst Ratings
The price target is $45.21 and the stock is covered by 16 analysts.
Buy
15
Hold
1
Sell
0
Information
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
- Employees
- 268
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US77313F1066
- Primary Ticker
- RCKT